Drug Information

Drug General Information
Drug ID
D00XCX
Former ID
DIB001563
Drug Name
DIFLOMOTECAN
Synonyms
BN-80915; R-1536; Diflomotecan < Prop INN >; (+)-5(R)-Ethyl-9,10-difluoro-5-hydroxy-4,5,13,15-tetrahydro-1H,3H-oxepino[3',4':6,7]indolizino[1,2-b]quinoline-3,15-dione
Drug Type
Small molecular drug
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 2 [521592]
Structure
Download
2D MOL

3D MOL
Formula
C21H16F2N2O4
Canonical SMILES
CC[C@@]1(O)CC(=O)OCC2=C1C=C3N(Cc4cc5cc(F)c(F)cc5nc34)C2<br />=O
InChI
1S/C21H16F2N2O4/c1-2-21(28)7-18(26)29-9-12-13(21)5-17-19-11(8-25(17)20(12)27)3-10-4-14(22)15(23)6-16(10)24-19/h3-6,28H,2,7-9H2,1H3/t21-/m1/s1
InChIKey
LFQCJSBXBZRMTN-OAQYLSRUSA-N
CAS Number
CAS 220997-97-7
PubChem Compound ID
219023
Target and Pathway
Target(s) Toposisomerase-1 Target Info Inhibitor [529845]
NetPath Pathway IL2 Signaling Pathway
PANTHER Pathway DNA replication
Pathway Interaction Database Caspase Cascade in Apoptosis
WikiPathways Integrated Pancreatic Cancer Pathway
References
Ref 521592ClinicalTrials.gov (NCT00080015) Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC). U.S. National Institutes of Health.
Ref 529845Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009 Jan;18(1):69-75.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.